{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-25-000131","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.288567+00:00","generated_at":"2026-05-16T23:51:43.074316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025","bullets":["Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).","Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.","Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.","Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.","RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-25-000131","json":"https://secwatch.observer/filing/0001739410-25-000131.json","markdown":"https://secwatch.observer/filing/0001739410-25-000131.md","text":"https://secwatch.observer/filing/0001739410-25-000131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/0001739410-25-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:51:43.074316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}